Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK-119
- Development stage
- Unknown
- Lead developer
- Akaal Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AK-119 is a novel oral small molecule agonist of the Sphingosine-1-Phosphate receptor subtype-1 (S1P1), developed by Akaal Pharma. It is primarily being investigated for the treatment of multiple sclerosis (MS), neuropathic pain, and pruritus associated with atopic dermatitis. Unlike first-generation S1P receptor modulators like fingolimod, AK-119 has demonstrated a differentiated safety profile in Phase I clinical trials, showing no evidence of bradycardia, dyspnoea, or severe immune suppression. Preclinical studies in MS models suggest that AK-119 maintains therapeutic efficacy while offering a superior safety margin.
02
Targets
EDG1 (Sphingosine-1-phosphate receptors)
Beyond the preview
Go deeper on AK-119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK-119.